SCHEMBL467905

SCHEMBL467905

CCOC([SiH3])OCC.CNC1CCCCC1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SHBG P04278 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
THRB P10828 1/20 0.33
ATM Q13315 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
MMP1 P03956 1/20 0.32
MMP2 P08253 1/20 0.32
EPHX1 P07099 2/20 0.32
KDM4E B2RXH2 2/20 0.31
ALDH1A1 P00352 4/20 0.31
SIGMAR1 Q99720 2/20 0.31
HSD17B10 Q99714 1/20 0.31
LMNA P02545 1/20 0.30
GAA P10253 1/20 0.30
MEN1 O00255 1/20 0.30
NPC1 O15118 1/20 0.30
MAPT P10636 1/20 0.30
HPGD P15428 1/20 0.30
RAB9A P51151 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL56309 0.78 ALDH1A1 (0.35) NPSR1KDM4EALDH1A1SIGMAR1HSD17B10
Ether SCHEMBL28087840 0.77 THRB (0.38) SHBGNPSR1THRBATML3MBTL1
SCHEMBL17041908 0.73 ALDH1A1 (0.47) EPHX1KDM4EALDH1A1SIGMAR1HSD17B10
SCHEMBL17046101 0.73 ALDH1A1 (0.47) EPHX1KDM4EALDH1A1SIGMAR1HSD17B10
SCHEMBL13166298 0.73 ALDH1A1 (0.53) EPHX1KDM4EALDH1A1SIGMAR1HSD17B10
SCHEMBL8918 0.73
SCHEMBL1148684 0.73
SCHEMBL3036481 0.73 ALDH1A1 (0.53) EPHX1KDM4EALDH1A1SIGMAR1HSD17B10
SCHEMBL3035987 0.73 ALDH1A1 (0.53) EPHX1KDM4EALDH1A1SIGMAR1HSD17B10
SCHEMBL13166302 0.73 ALDH1A1 (0.53) EPHX1KDM4EALDH1A1SIGMAR1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 500 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3081612-B1 PHOTOCURABLE COMPOSITION HAVING ADHESIVE PROPERTIES CEMEDINE CO LTD (JP) 2018-11-14 EP claimed
US-8815985-B2 Curable composition KANEKA CORPORATION (JP) 2014-08-26 US claimed
EP-4727982-A1 PRIMER COMPOSITION, ADHESIVE SYSTEM, AND RELATED PROCESSES 3M Innovative Properties Company (US) 2026-04-22 EP disclosed
EP-3585851-B1 AIR AND WATER BARRIER ARTICLE INCLUDING INELASTIC POROUS LAYER 3M INNOVATIVE PROPERTIES COMPANY (US) 2026-04-01 EP disclosed
EP-4703405-A1 CRYSTALLINE POLYOXYALKYLENE-BASED POLYMER AND CURABLE COMPOSITION COMPRISING SAME Kaneka Corporation (JP) 2026-03-04 EP disclosed
EP-4692247-A1 CURABLE COMPOSITION KANEKA CORPORATION (JP) 2026-02-11 EP disclosed
US-12545691-B2 Tertiary hydroxyl functional alkoxysilanes and methods for preparing thereof HENKEL AG & CO. KGAA (DE) 2026-02-10 US disclosed
US-20260022211-A1 CURABLE COMPOSITION KANEKA CORPORATION (JP) 2026-01-22 US disclosed
EP-4682204-A1 CURABLE COMPOSITION Kaneka Corporation (JP) 2026-01-21 EP disclosed
EP-3929260-B1 CURABLE COMPOSITION KANEKA CORP (JP) 2025-12-17 EP disclosed
EP-4656672-A1 METHOD FOR PRODUCING CURABLE COMPOSITION Kaneka Corporation (JP) 2025-12-03 EP disclosed
EP-1746134-A1 CURABLE COMPOSITION WITH IMPROVED CURABILITY AND ADHESIVENESS Kaneka Corporation (JP) 2007-01-24 EP disclosed
EP-1746133-A1 CURABLE COMPOSITION IMPROVED IN ADHESIVENESS Kaneka Corporation (JP) 2007-01-24 EP disclosed
EP-1736511-A1 CURABLE COMPOSITION KANEKA CORPORATION (JP) 2006-12-27 EP disclosed
EP-1734079-A1 SINGLE-COMPONENT CURABLE COMPOSITION Kaneka Corporation (JP) 2006-12-20 EP disclosed
EP-1731574-A1 SINGLE-COMPONENT CURABLE COMPOSITION KANEKA CORPORATION (JP) 2006-12-13 EP disclosed
EP-1731573-A1 CURABLE COMPOSITION KANEKA CORPORATION (JP) 2006-12-13 EP disclosed
US-20060252903-A1 Curing composition KANEKA CORPORATION 2006-11-09 US disclosed
US-20060089432-A1 Curable composition KANEKA CORPORATION (JP) 2006-04-27 US disclosed
EP-1624027-A1 CURING COMPOSITION KANEKA CORPORATION (JP) 2006-02-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12545691-B2 Tertiary hydroxyl functional alkoxysilanes and methods for preparing thereof HCCS, EGLN1, RRS1 SHBG 673/4885NPSR1 1391/4885THRB 285/4885
US-20260022211-A1 CURABLE COMPOSITION H1-4, H1-0, H1-2 SHBG 1856/4885NPSR1 4282/4885THRB 1451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.